United Therapeutics Chairperson and CEO Martine A. Rothblatt Reports Disposal of $5.08 Million in Common Shares
Bitget2026/10/19 20:35- United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 common shares on October 16, 2026.
- Rothblatt also exercised stock options for 9,500 common shares at $117.76 per share on the same date.
- The transactions left 324,443 common shares held indirectly through trusts involved in the trades; direct holdings totaled 40,513 shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Under election pressure, Trump launches another $8 billion diesel subsidy targeting votes in agricultural states
The Trump administration has announced the launch of an 8 billion USD "Harvest Fuel Relief Program," which will provide one-time subsidies to help farmers offset higher diesel costs resulting from tensions in the Middle East. The program distributes funds according to a unified formula and will only partially compensate for losses. Analysts point out that this move is a political measure aimed at consolidating agricultural state votes ahead of the midterm elections, and question the feasibility of the funding.

GBP/USD Price Forecast: Reflects strength above 20-day EMA ahead of UK job data

CoreWeave (CRWV.US) plunges 15%: Citi (C.US) says rate pressures hit Neocloud, Microsoft (MSFT.US) cash flow advantage stands out
CoreWeave plunged 15% in a single day, triggering market volatility. Citi analyst Tyler Radke pointed out that high borrowing costs are severely impacting Neocloud companies that rely on debt financing. In contrast, Microsoft demonstrates notable resilience during the AI funding tightening cycle thanks to its strong free cash flow and debt-free advantage.

SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns
Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.
